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MYELOABLATIVE CONDITIONING WITH TBI/VP-16 WITH ALLOGENE- 
IC STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA: HIGH 
RESPONSE RATE AND PROLONGED PROGRESSION FREE SURVIVAL 
GoldsteiJl, S.C.; PerkiJ~s, J.; Field, 72; .Tam'sell, ~V.; Als'i~a, I.; &dli- 
va,*, D.; Fields', K.; Smith, C. H. Lee Moffitt Ca~ce'l" Ce~te'l" aJzd 
Researeh IHstimte at the UMversity of SoHth Florida, Tampa, FL. 
Although High Dose Therapy with autologous peripheral blood 
stem cell transplantation has improved the complete response rates 
and overall survival for patients with Multiple Myelolna (MM), mak- 
ing it the standard of care for many patients (pts) with chemosensitive 
disease; autotransplantation has not demonstrated curative potential 
despite xtensive valuation with long-term follow-up. Despite the 
demonstration f an immunologic graft vs myeloma effect, the overall 
success of myeloablative conditioning with allogeneic transplantation 
for patients with MM has been limited hy treatment related mortality 
(TRM) as well as relapse. Whereas novel strategies such as non-mye- 
loablative conditioning may lower the early TP~M, they have thus far 
have had only marginal success in long term disease control. Novel 
myeloablative conditioning regimens with acceptable to ,  city car W 
the potential advantage of tumor cytoreduction a d establishment of 
donor chimerism to improve long term disease control. We report 
the long term follow-up of 14 consecutive patients with MaVI who 
have undergone myeloablative conditioning witln either BuCy2 (n=7) 
or TBI/VP-16 (n=7) followed by allogeneic bone nmrrow stem cell 
transplantation fi'om HLA-identical sibling donors. Median age for 
all patients i 46 years. The probability of Overall Survival (OS) at 2.5 
years for all patients, BuCy2 pts, and TBI/VP-I6 pts is 36% (SE 
13%), 14% (SE 13%), and 57% (SE I9%), respectively. The proba- 
bility of Event Free Survival (EFS) at 2.5 yrs is identical to the OS. 
Of note, the probability of Progression-Free Survival (PFS) at 2.5 
years, in which treatment related deaths are censored, is 78% (SE 
14%) for all pts, 50% (SE 25%) for BuCy2 pts, and 100% for 
TBI/VP-16 pts. Surviving patients after myeloablative conditioning 
have been followed without relapse for a minimum of 4 years. 100 day 
TPdVI for all pts was 28%. Although this analysis is limited by sample 
size, these results demonstrate prolonged disease free survival for pts 
with MM after myeloablative conditioning with hig'h dose TBI/VP- 
16 followed by allogeneic stem cell transplantation. This regimen is 
well tolerated and warrants further investigation as a potentially cura- 
tive strategy in young MM patients with HLA-identical donors. 
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NON-MYELOABLATIVE STEM CELL TRANSPLANTATION (SCT) IS SAFE 
AND EFFECTIVE FOR PATIENTS WITH MULTIPLE MYELOMA 
Mm'eb, J.s.l; Cogle, C.RJ; Leather, H.L.e; Wiggins, L.~-; Fi1~iewiez, 
K.J.~; Kha*z, S.A.~; Reddy, ~':S.e; ~'t')'J~gard, ff.R. ~ 1. ~J)#vevsitj of 
FloT"ida College of Medici1~e, GaiT~esville, FL; 2. Shallcls Hospital Braze 
3la'lvvoa, TvaJzsplaT~a Program, Gai,~esville, FL. 
Allogeneic SCT can be curative in multiple myeloma (NLM), 
however the high transplant related morbidity and mortality 
(TRM) limit this therapy to young, low-risk patients. Purpose: 
The purpose of this study was to determine safety and efficacy of 
non-myeloablative stem cell transplant (NST) for high-risk 
patients with MM. Patients and Methods: From September 1999 
to June 2001, eight MM patients with a median age of 49 years 
(range, 44 to 62), received allografts from HLA-matched siblings 
(n=6) or unrelated onors (n=2). Prior to NST none were in com- 
plete remission (CR) and 4 had progressive disease (PD). Six 
patients had a prior autologous transpFant. Median time from 
diagnosis to NST was 33 months (range , 5 to 64). The condition- 
ing regimen included flndarabine, finti-thymocyte globulin and 
busulfan. Peripheral blood stem cell grafts were administered to
all patients. Results: All patients had prompt myeloid and platelet 
engraftment. Acute graft versus host disease (GVHD) (three grade 
I, two grade IIi) occurred in 5 of 8 patients (62%), at a median 
time of 26 days (range, 11 to 106 days). Four patients (50%) 
developed chronic GVHD (2 limited, 2 extensive). Two patients 
with no GVHD and PD received onor leukocyte infusion (DLI) 
(lxl0 s CD3/kg). One patient receiving DLI subsequently devel- 
oped grade I acute GVHD. The conditioning regimen was well 
tolerated with no patients developing VOD or severe mucositis. 
During neutropenia, only one patient developed a line-associated 
gram positive bacteremia. While on immunosuppressants, seven 
patients developed opportunistic nfections, including CMV and 
HSV colitis, cutaneous zoster, polyoma BK cystitis, mucocuta- 
neous candidiasis, puhnonary aspergillosis and Strongyloides 
infection. Only one patient died of opportunistic infection. With a 
median follow-up of 13 months, three (38%) achieved CR, two 
(25%) PR, one MR, one SD, and one PD. M1 disease responses 
were observed after development of GVHI). Two patients (25%) 
died before 100 days: one of CNS failure secondary to possible 
FK506 toxicity and another due to opportunistic lung infection. 
One year EFS and OS are 50% and 75%, respectively. Conclu- 
sions: NST with fludarabine, anti-thymocyte globulin and busul- 
fan conditioning is well tolerated in high>risk patients with MM. 
In addition, agraft versus lnyeloma effect is obsmwed. 
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A PILOT STUDY OF MYELOABLATIVE (MA) AUTOLOGOUS STEM CELL 
TRANSPLANTATION (AUTO SCT) FOLLOWED BY REDUCED INTENSI- 
TY (RI) ALLOGENEIC TRANSPLANTATION (ALLO SCT) IN CHILDREN 
AND YOUNG ADULTS WITH RELAPSED LYMPHOMA 
Bradley, 31.; Hal"l"isoT1, L.; George, D.; Ga'l'viJz, ft.; Del Tovo, G.; 
Wolozwdk, K.; CTJe~mg, }:; WeiTler, 3'1.; Kelly, 1,2; Sleervitt, D.; G#~'o, 
M.S. Cbildre~'s Hos'pital of Nezv Yo*'/e PJ'e,rl{yteJ'#m, New Y0r'k, NI~ 
Patients with relapsed I tD and NHL treated with MA 
AutoSCT have a high risk of relapse (40-60%) and secondary 
MDS/AML (5-20%). MA AlloSCT may confer a graft versus lym- 
photos effect but with considerable regimen-related mortality 
(Jones et al, Blood 77:649, 1991). Recently, Carella et al (JCO 
18:3918, 2000) demonstrated the feasibility of MA AutoSCT fol- 
lowed by RI AlloSCT in adults with refractory HD. X/Ve investi- 
gated MA AutoSCT followed by RI AlloSCT in relapsed pediatric 
HD/NHL. MA: Cyclo 1500 mg/m 2 x 4d, BCNU 100 nlg/ln 2 x 3d, 
VP-16 800 mg/m 2 x 3d, and AntoSCT. After recovery, patients 
with CD20 + lymphoma (3/4) received Rituximab (375 
mg/me/wk/x 4), and all patients received IFRT (2-3 Gy). RI: Flu 
30 mg/m 2 x 5d, Bn 3.2 mg/kg x 2d, and Thymoglobulin® 2.0 
mg/kg x 4d (UCB recipients only) and MloSCT (1 related 6/6 
PBSC, 3 4/6 UCB). GVHD prophylaxis: FK506 (0.03 mg/kg 
CM)  on day-1 - +60 (wean started) and MMF (15 lng/kg) day +1 
- +28. There were 3 t tD (2 CR + 1 PR after Ifos/Carbo/Etop 
reinduction), age 17, 18, and 22 years, 1 stage IIA, 1 stage IIIB, 1 
stage IVA, and I anaplastic large cell ymphoma (ALCL) (PR after 
Topo/Ifos/Carbo reinduction) age 11. Tandem MA AutoSCT + 
RI MloSCT was well tolerated. Median time to RI MloSCT after 
MA AutoSCT was 124 d. Median F/U is 380 d. One pt has grade 
3 hematuria nd grade 2 pulmonary toxicity. Following RI 
MloSCT, myeloid recovery occurred on day +15 (MRD) day +15, 
+18, +23 (UCBT), platelet recovery on day +11 (MRD), day +25, 
+31, +170 (UCBT). The 3 HD patients have 100% donor 
chimerism and are NED at day +474, +286 and +473, respectively, 
and the pt with NHL is 95% donor and NED at day +140. No 
patient developed AGVHD. One patient developed limited 
chronic liver GVHD responding to alternating CSA + Pred. Esti- 
mated OS at 1 year is 100%. In conclusion, MA AutoSCT fol- 
lowed by IFRT, targeted monoclonal antibody therapy, and RI 
Mlo SCT is feasible and well tolerated in pediatric patients with 
relapsed HD/NHL.  A larger study with longer follow up is 
required to determine if this approach will reduce relapse and/or 
MDS and improve EFS. 
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THE CHOICE OF CONDITIONING REGIMEN REGARDING THE HOST T- 
CELL LEVELS SEEMS TO BE AN EFFECTIVE WAY HOW TO ACHIEVE 
THE DONOR CELLS ENGRAFTMENT INCLUDING EFFECTIVE TUMOUR 
C*ONTROL AND REDUCE THE TOXICITY OF SOME NON-MYELOABLA- 
TIVE ALLOGENEIC STEM CELL TRANSPLANTATIONS IN LYMPHOMAS 
Raids, L.; Faber, E.; Papajfk, 72; Heczko, M.; Skolmlalovd, I.; Pikalovd, 
Z.; Jaroovd, 3/I.; Koztpilovd, 3 i.; ~'7achovd, .; Kltbahikovd, R.; Di'coted, ~I., 
h~d~vik, I(; Htcbd?ek, ,7. mdversi O, Hospital, Olo~.oztc, Czech RepTzblic. 
"Graft versus iymphoma" (GvL) reaction plays the key role in 
the tmnonr control of patients undergoing allogeneic stem cell 
122 
Poster  P resentat ions  - Sess ion  I I  
transplantation (SCT) for lymphomas and the engraftment of 
donor immnnocompetent cells is essential. The height of host 
"immunological barrier" belongs to the major factors influencing 
engraftment. Some patients transplanted after non myeloablative 
regimens finally reconstituted their own immunocompetent cells 
because of insufficient immunosuppression and there has been no 
room for GvL effect. On the other hand, many pretrcated 
immunocompromised r cipients developed severe complications 
due to unnecessary toxicity. 11 patients with non-hodgkin lym 
pbomas (NHL - 8x) and chronic lymphatic leukemia (CLL - 3x) 
underwent non-myeloablative allogeneie SCT fronl sibling donor. 
No one of them was in complete remision (CR) before SCT. The 
recipients with the pretransplant level of CD3+ cells below than 0, 
5x10 9/L were grafted after conditioning combined flndarabin 
(125rag/m2) and cyclophosphamide (120mg/kg). Those ones with 
CD3+ cells above 0, 5x10 9/L underwent SCT after fludarabin 
and melphalan (140rag/m2), fludarabin, melphalan and ATG 
(40mg/kg)or fludarabin, cyclophosphamide and ATG. The "graft 
versus host disease" (GvHD) prophyla~s consisted of cyclosporine 
A (CsA) only or CsA combined with the short-course of 
methotrexate (MTX). Donor chilnerism was evaluated in T-cell 
population at day +30, +60, +100 after SCT. CsA tapering 
depended on the grade of donor chimerism in T-cells. 10 patients 
(90, 0%) achieved complete donor chimerism in T-cells and sus- 
tained CR of their disease at the posttransplant follow-up period 
(median 134 days). 6 recipient (54, 5%) developed GvHD. 3 
patients (27, 3%) died of transplant-related complications. The 
combination of fludarabin and cyclophosphamide (+/- ATG) was 
associated with significantly lower to ,  city and allowed sufficient 
engraftment of donor cells with effective immunological mmour 
control in severe immunocompromised hosts. The reduction of 
conditioningorelated o,city without he decrease of CR rate fully 
advocate the pretransplant evaluation of T-cell populations in 
recipients. 
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COMPARISON OF THREE CONDITIONING REGIMENS FOR AUTOLOGOUS 
STEM CELL TRANSPLANTATION IN NON-HODGKINS LYMPHOMA 
Fein, S.G.; O[,ersteim E., GoochnaJ1, M.; Byrnes, J.; Fe1"mmde~, H.F. 
Hemc/tolo~JO71cologv, Uniz,e'rsio~ of3/lkmli, ~ limni, FL. 
The optimal conditioning regimen for non-Hodgkins Lynx- 
phoma (NHL) patients receiving autologous helnatopoietic stem 
cell (HSC) transplantation remains uncertain. In many centers, 
cyclophosphamide and total body irradiation (FBI) have been 
replaced by combination chemotherapy regimens. One of these is 
busulfan(BU) and oyclophosphamide(CY). Recent studies suggest 
that intravenous busulfan may be more efficacious than oral busul- 
fan, partly attributable to more predictable pharmacokineties. To 
compare these conditioning regimens, we reviewed 63 autologous 
HSC transplants performed at our institution fi'om 1994-2002. 
Among these, 22 patients with NHL (73 % interinediate or high 
grade) were treated with cyclophosphamide 120 mg/kg and TBI 
1200 cGy given as divided daily fractions for 3 days (Cy/TBI), 18 
patients (78% intermediate grade) with oral busulfan 16 mg/kg 
and eyclophosphamide 120 mg/kg (Oral Bu/Cy), and 23 patients 
(91% intermediate grade) with intravenous busulfan I2.8 mg/kg 
with cyelophosphamide 120 mg/kg (IV Bu/Cy). The median age 
for each of the three groups was comparable. The groups differed 
with respect o number of pre-transplant chemotherapy treat- 
ments- 36% of Cy/TBI heavily pre-treated (more than 8 cycles of 
chemotherapy), compared to 64% of oral Bu/Cy and 77% of IV 
Bu/Cy. The IV Bu/Cy patients were more likely to be pre-treated 
with rituximab (45%) than Cy/TBI (0%) and oral Bu/Cy (6%). 
Treatment-related toxicity and mortality were comparable, 
though both busulfan cohorts had a longer time to engraftment. 
Median follow-up times were 7.1 years (Cy/TBI), 3.6 years (oral 
Bu/Cy), and 2.1 years (IV Bu/Cy). Overall (OS) and relapse-free 
survivals (RFS) at two years were 77% and 59% (Cy/TBI), 61% 
and 56% (oral Bu/Cy), and 71% and 71% (IV Bu/Cy). Although 
follow-up is short, Kaplan-Meier survival analysis suggests a trend 
towards improved RFS among IV Bu/Cy patients. Log-rank com- 
parison of the OS curves reveals no significant,difference amongst 
the three groups. Based on this review, the to,city and efficacy 
are comparable using IV Bu/Cy, Cy/TBI or oral Bu/Cy, as the 
conditioning regimen in autologous HSC transplant for NHL. 
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AUTOLOGOUS HENATOPOIETIC STEM CELL TRANSPLANTATION FOR 
TREATMENT OF MULTICENTRIC CASTLEMAN'S DISEASE/POEMS 
SYNDROME 
ChaTnm'thy, U.; ffmmkirnma'a, N.; tGnnboj, G.; AbdeLRnheem, M.; 
Rl~y, ti2; Pnrikh, D. Hem / 07zc / BMT, Hem 7 FoJ'd He~dth @stem, 
Detroit, 1~iI. 
BACKGROUND: POEMS (polyneuropathy, organomegaly, 
endocrinopathy, M proteiu, skin changes) syndrome, a rare nmlti- 
systemic disorder, is associated with nmlticentric Castleman's dis- 
ease (MCD) in 50% of cases. The treatment of MCD remains a 
challenge. There have been reports of limited and variable effective- 
ness using steroids, chemotherapy and imlnnnomodnlators (anti- 
IL6, interferon, Rituximab). There has only been one previous case 
report (Repetto et al. 1986) using" HDCT/HSCT. We report a case 
of MCD/POEMS successfully treated with high dose chemothera- 
py (HDCT) and hematopoietic stem cell transplantation (HSCT). 
CASE RESENTATION: A previously healthy 24 year-old male 
presented witb a rapidly progressing (demyelinating/axonal) eu- 
ropathy, initially involving the lower, and eventually the upper 
extremities - around November 2000. Within three months the 
patient became wheel-chair bound (ECOG Performance status=4), 
developed generalized lymphadenopathy, hepato splenomegaly and 
gynecomastia. Lymph node and bone marrow biopsies were non- 
diagnostic. He undei~vent splenectomy in May, 2001. The patholo- 
gy showed angiofollicnlar hyperplasia consistent with Castleman's 
disease. He had low testosterone levels, Ig A ~ monoclonal protein 
in the serum, and cutaneous helnangiomas. Serologic screening for 
HIV and IIHV-8 were negative. With these findings, a diagnosis of 
MCD/POEMS was established. Therapeutic trials of steroids, Rit- 
nximab, IVIG, Cyelophosphamide/prednisone failed. Given his 
young age and rapid clinical deterioration he was offered high dose 
chemotherapy with HSCT. Peripheral blood stem cells were har- 
vested using Cyclophosphamide (3g/mZ)/G-CSF (10~tg/Kg). The 
patient was given Melphalan (200mg/m -~) as conditioning regimen, 
followed by antologons tem cell infusion. Hospital course was 
complicated by febrile neutropenia and choleeystitis. Clinical and 
radiological resolution of all lymphadenopathy occurred within 4 
weeks. He also had gradual recovery of his neurological deficits and 
hepatomegaly. The patient remains in remission a year later 
(ECOG PS=0) CONCLUSION High-dose chemotherapy with 
autologous hematopoietic stem cell transplant resulted in complete 
remission of aggressive and refractory MCD/POEMS syndrome 
with a durable response at one year. HDCT/HSCT is a novel treat 
ment option for this rare but challenging disease. 
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CD34+ COUNTS AFTER ETOPOSIDE AND CYCLOPHOSPHAMIDE PLUS 
G-CSF MOBILIZATION VERSUS G-CSF ALONE IN MULTIPLE MYELOMA 
PATIENTS UNDERGOING AUTOLOGOUS TRANSPLANTATION 
Pie'rce, T.N[; Scott, L.M.; White, M.; Agv~'_n, E.; Bero,mlm, R.B.; Ftlv, 
J. t,f,~; ~mzce, E.; Ph~eiro, L. . 
There were 83 patients who had an autologous transplant for 
multiple myeloma. All patients had a myeloablative r gimen with 
26 (31%) receiving" Melphalan, 55 (66%) received 
Melphalan/Total Body Irradiation (TBI). There was 1 patient 
who received ThioTepa/TBI and 1 who received Cyclophos- 
phamide/TBI as the conditioning regimen. Of the 83 pts, there 
were 58 (70%) who received mobilization with a continuous infu- 
sion of etoposide (2400mg/m2 over 34 hours) followed by 
cyclophosphamide 150 mg/kg followed by G-CSF at a dose of 5 
mcg/kg/day. There were 25 patients (30%) that received mobi 
lization with G-CSF only at a dose of 16 mcg/kg/day. For the 
patients who received chemotherapy mobilization, the average 
nmnber of PBSC collections required was 1.8 (Range 1 to 7, 
median=l). Of the patients who received G-CSF mobilization, the 
average number of collections was 2.8 (Range 1 to 5, median=2). 
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